What is the recommended medical expulsive therapy for an impacted ureteral stone?

Medical Expulsive Therapy for Impacted Ureteric Stones

Alpha-blockers (particularly tamsulosin) are the recommended medical expulsive therapy for impacted ureteral stones, with the greatest benefit for distal stones larger than 5 mm. 1

Primary Pharmacological Agent

• Alpha-blockers are the preferred agents for medical expulsive therapy (MET), demonstrating a statistically significant 29% increase (CI: 20% to 37%) in stone passage rates compared to controls. 1
• Tamsulosin is the most commonly studied alpha-blocker, though terazosin and doxazosin appear equally effective. 1
• The mechanism involves ureteral smooth muscle relaxation through alpha-1 receptor blockade, facilitating stone passage. 1

Stone Size Considerations

The effectiveness of alpha-blockers varies significantly with stone size:

• For stones >5 mm: Alpha-blockers demonstrate substantial benefit (RR 1.44,95% CI 1.22-1.68), making them strongly recommended. 2, 3
• For stones ≤5 mm: The benefit is minimal to absent (RR 1.08,95% CI 0.99-1.68), with questionable clinical utility. 2, 3
• Optimal indication: Distal ureteral stones 5-10 mm in diameter show the greatest therapeutic response. 1, 4, 3

Stone Location Specificity

• EAU guidelines recommend alpha-blockers particularly for distal ureteral stones greater than 5 mm. 1
• AUA guidelines recommend MET for distal ureteral stones only, not for proximal or mid-ureteral locations. 1
• The anatomical distinction is important because distal stones have higher spontaneous passage rates that can be further enhanced with MET. 1, 5

Alternative Agents (Less Effective)

• Nifedipine (calcium channel blocker) shows only marginal benefit with 9% improvement (CI: 7% to 25%), which was not statistically significant. 1
• Calcium channel blockers have pooled risk ratios of 1.90 (1.51 to 2.40) but are not preferred over alpha-blockers. 1
• Corticosteroids provide minimal additional benefit when added to alpha-blocker therapy. 1

Treatment Duration and Monitoring

• Maximum conservative treatment duration should be 4-6 weeks from initial clinical presentation to avoid irreversible kidney injury. 1
• Mandatory follow-up is required during the observation period with MET. 1
• If conservative management with MET fails, proceed to definitive surgical intervention (URS or SWL). 1

Additional Benefits Beyond Stone Passage

Alpha-blockers provide multiple therapeutic advantages:

• Reduced stone expulsion time by approximately 3.4 days (MD -3.40 days, 95% CI -4.17 to -2.63). 2
• Decreased analgesic requirements, with reduced diclofenac use (MD -82.41,95% CI -122.51 to -42.31). 2
• Lower hospitalization rates (RR 0.51,95% CI 0.34 to 0.77), corresponding to 69 fewer hospitalizations per 1000 patients. 2
• Reduced number of pain episodes during the stone passage period. 1

Safety Profile and Adverse Events

• Major adverse events are slightly increased with alpha-blockers (RR 2.09,95% CI 1.13 to 3.86), corresponding to 29 additional major adverse events per 1000 patients. 2
• Overall side effect incidence does not differ significantly from controls (RR 1.14,95% CI 0.86-1.51). 2
• Patients must be informed about off-label use of alpha-blockers for this indication and potential side effects. 6, 5

Post-Lithotripsy Application

• Alpha-blockers are recommended after shock wave lithotripsy (SWL) to facilitate passage of stone fragments. 1
• This application extends the utility of MET beyond primary stone management to post-procedural care. 1

Clinical Caveats

Important limitations to consider:

• Recent large, high-quality placebo-controlled trials have raised questions about MET effectiveness, particularly for smaller stones. 6, 2
• The benefit appears most robust in the 5-10 mm stone size range in the distal ureter. 1, 4, 3
• Do not delay definitive treatment beyond 4-6 weeks even if MET is being used, as prolonged obstruction risks permanent renal damage. 1